The Drug Discovery report series

This drug discovery series tackles the issues impeding innovation for R&D executives and assesses the cutting edge approaches and technologies companies can use to overcome the productivity gap.

The Emerging Role of Postmarketing Clinical Research
'The Emerging Role of Postmarketing Clinical Research’ is a new report published by Business Insights that uses detailed case studies and market scenarios to examine the latest issues surrounding phase IV trial applications. The potential to leverage competitive advantage with postmarketing research is assessed by measuring the implications for formulary access, product marketing, indication expansion and reimbursement coverage.
Table of contents | Brochure | More information

Innovative Clinical Trial Design and Management
‘Innovative Clinical Trial Design and Management’ is a new report published by Business Insights that explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA.
Table of contents | Brochure | More information

The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less.
Table of contents | Brochure | More information

Innovations in Bioinformatics: Emerging tools for drug discovery and development
R&D laboratories are co-ordinating the analysis of increasingly prohibitive volumes of disparate biological data, much of which is comprised of gene and protein sequences. Companies are now integrating bioinformatics-enabled data management to tackle this deluge and improve productivity within their R&D programmes by identifying new drug targets, biomarkers of drug efficacy and toxicity, and diagnostic biomarkers.
Table of contents | Brochure | More information

Nanotechnology: Revolutionizing R&D to develop smarter therapeutics and diagnostics
Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotehnology market to over a trillion dollars by 2015
Table of contents | Brochure | More information

Translational Medicine in Biopharmaceutical R&D
As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research...
Table of contents | Brochure | More information

Drug Development Opportunities in China
Identify the factors attracting global drug developers to China, assess future growth opportunities within the domestic pharma and biotech markets and deploy outsourced R&D more effectively with this new report...
Table of contents | Brochure | More information

Immunomodulators: Therapeutic Needs, Pipelines & Prospects
The strategies and technologies used in immunomodulation are analysed and the major clinical applications of immunomodulators are reviewed to identify the leading drug classes and most promising agents currently in development.
Table of contents | Brochure | More information

Outlook for RNAi, 2007: siRNA and miRNA in biology, diagnostics and therapeutics
The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials.
Table of contents | Brochure | More information

Drug Repositioning Strategies: Innovative strategies to boost pipeline productivity
This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them,
Table of contents | Brochure | More information

Next Generation Protein Engineering and Drug Design
This report provides a detailed insight into the current market for engineered proteins and peptides, and explores the key factors of commercial success for the development of next generation products.
Table of contents | Brochure | More information

Biopartnering Strategies: Maximizing returns from biotechnology deal-making
Use this report to implement the optimal biopartnering strategy for your company’s needs as it progresses through the ‘pioneer’, ‘growth’ and ‘consolidation’ stages.
Table of contents | Brochure | More information

Winning R&D Productivity Strategies
Use this report to identify key areas of growth, effective strategies and innovative technologies to improve lead generation.
Table of contents | Brochure | More information

The Future of Metabolomics: Building competitive advantage in drug discovery...
Explore potential cost savings, and recognize lucrative partnering opportunities in this fast moving field with this report.
Table of contents | Brochure | More information

Commercial Opportunities from Biomarkers
This report will ensure that you are able streamline your R&D process and identify potential cost savings throughout drug discovery and development.
Table of contents | Brochure | More information

Opportunities in Stem Cell Research
Identify potential alliance partners and plan a long-term growth strategy to secure your leading position in this market. with this report.
Table of contents | Brochure | More information

Predictive ADME and Toxicology Strategies
This report focuses on how novel predictive toxicology and ADME methods can provide a better return on investment and reduce drug attrition rates in clinical trials.
Table of contents | Brochure | More information

The Emerging Drug Targets Outlook
Drug targets are generally proteins. Nucleic acids are possible drug targets, and approaches such as RNA interference (RNAi) may indeed have advantages over proteins, but they have not so far been developed extensively.
Table of contents | More information

The Future of Systems Biology: Emerging technologies and their impact on drug discovery...
This report will help you to maximize the cost and time saving benefits offered by biological systems in these areas to secure your frontline position in the marketplace.
Table of contents | Brochure | More information

The Future of Array Technologies
This report reviews recent M&A activity in the array market, enabling you to identify synergies and competitive advantages that can be achieved through collaboration.
Table of contents | Brochure | More information

Lead Optimization Strategies
This report details important service providers for lead optimization outsourcing used by the pharmaceutical industry, in order to address the rising costs of drug development and improve drug attrition rates.
Table of contents | Brochure | More information

The Outlook For RNAi: Accelerating drug discovery....
This report analyzes future trends of RNAi and provides detailed insight into the most effective use of this novel technology in the drug discovery process .
Table of contents | Brochure | More information

Emerging Drug Discovery Technologies
Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi, is a new report which provides an in-depth analysis of three technological innovations that are being heralded to revolutionize the drug discovery process by rapidly expediting drug discovery research.
Table of contents | Brochure | More information